Agenda
11:00 AM — 12:30 PM
Session 2A: Control Strategy for Double-Stranded Oligonucleotides10:30 AM — 12:00 PM
Session 6A: Thinking Ahead: Oligonucleotide Drug-Device Combination Products1:30 PM — 3:00 PM
Session 7A: Recently Approved and Late-Stage Oligonucleotide Drugs8:00 AM — 9:30 AM
Session 9A: Interactive Discussion of CMC Challenges and Moving ForwardHave an account?